Skip to main content
Rize RecoveryThe Newsroom
Science & Medicine· Research Roundup

The Largest Medicinal Cannabis Review Yet Finds No Benefit for Anxiety, Depression, or PTSD

And researchers say the marketing is getting ahead of the evidence — particularly for people with existing substance use disorders

ByThe Rize NewsroomMay 21, 20262 min readCannabinoids

The Study

A systematic review published in March 2026 — among the largest ever conducted on the clinical effects of medicinal cannabis — concluded that current evidence does not support cannabis as an effective treatment for anxiety, depression, or post-traumatic stress disorder. The researchers further warned that cannabis may worsen mental health in some individuals, particularly by increasing the risk of psychosis and by delaying engagement with treatments that have well-established evidence bases.

The findings come as cannabis has increasingly been marketed and self-prescribed for exactly these conditions, with patients in several U.S. states able to qualify for medical cannabis cards by citing anxiety or PTSD.

What the Science Does and Doesn’t Show

The review is careful to distinguish between the pharmacological effects of CBD and whole-plant or THC-dominant cannabis products. Much of the positive sentiment around “medicinal cannabis” conflates these distinct pharmacological entities.

In parallel, a 2026 brain imaging study mapped the neurocircuitry of cannabis cue reactivity for the first time. Researchers found that people with cannabis use disorder showed heightened activation in the orbitofrontal cortex, cingulate, hippocampus, and cerebellum when viewing cannabis cues — a circuitry pattern that substantially overlaps with alcohol, nicotine, and cocaine use disorders.

Data from the ABCD Study — following more than 11,000 American adolescents — found that teens who use cannabis show slower improvements in memory, attention, language, and processing speed compared to non-users.

The Clinical Implication for Recovery

For the recovery community, people in treatment for other substance use disorders who are using cannabis to manage anxiety or PTSD may be relying on a tool that the evidence does not support — and that carries its own risk of dependence and mental health worsening. Over 100 peer-reviewed cannabis studies have been published in 2026 alone; the picture is not uniformly negative, but the marketing has outrun the evidence on mental health.

Sources Cited

  1. 01.A
    Huge study finds no evidence cannabis helps anxiety, depression, or PTSDScienceDaily

Filed Under

sciencebiology

Continue reading

More from this section

Science & Medicine

The Ego Goes Quiet, and So Does the Pattern: What Psychedelics Actually Do to the Psychology of Addiction

Psilocybin suppresses the default mode network. MDMA reduces amygdala reactivity during trauma processing. Ibogaine resets mu-opioid signaling. Here’s what the science says about the psychology of psychedelic therapy for addiction.

Science & Medicine

France Just Approved IV Ketamine for Suicidal Crisis. The US Has an Excuse, Not an Answer.

France’s ANSM became the first national regulator anywhere to authorize IV racemic ketamine for adult acute suicidal crisis. The US approved esketamine in 2019 but won’t standardize IV ketamine—because it’s a generic with no commercial sponsor.

Science & Medicine

The FDA Just Cleared the First US Ibogaine Trial. It Took 30 Years.

DemeRx received FDA IND clearance for noribogaine—an ibogaine metabolite—for alcohol use disorder. Dr. Deborah Mash has been waiting three decades for this regulatory opening.